Insulin immunotherapy for pretype 1 diabetes.

ABSTRACT:

Purpose of review

Loss of tolerance to insulin likely contributes to the immunopathogenesis of type 1 diabetes (T1D). Several large clinical trials and smaller mechanistic studies have failed to demonstrate the efficacy of insulin antigen therapy. The growing awareness of the heterogeneity of T1D likely affects the response to various immune therapies including insulin. Identification of biomarkers of clinical response will provide further insight into mechanisms leading to the disease and classify responders in the quest for personalized therapy.

Recent findings

Several biomarkers have identified subpopulations in posthoc analyses that showed benefit from oral insulin even though the placebo-controlled study was as a whole unsuccessful. High insulin autoantibody titer, low

SUBMITTER: Jacobsen LM 

PROVIDER: S-EPMC8244997 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature